National Academies Press: OpenBook
« Previous: Appendix B: Committee Meeting 2 Agenda
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

C

Committee Biographies

Brian L. Strom, M.D., M.P.H. (Chair), is the inaugural chancellor of Rutgers Biomedical and Health Sciences (RBHS) and the executive vice president for Health Affairs at Rutgers University. RBHS is comprised of eight schools and five centers/institutes, and includes academic, patient care, and research facilities. These are most of the units of the former University of Medicine and Dentistry of New Jersey (UMDNJ), now dissolved, several Rutgers University units with health-related missions, and two research units historically co-managed by Rutgers and UMDNJ. The integration of these entities is designed to create a single organization that will lead to new models for clinical care and community service, educate the next generation of health care providers utilizing health care team approaches, and conduct research. Dr. Strom was formerly the executive vice dean of Institutional Affairs, founding chair of the Department of Biostatistics and Epidemiology, founding director of the Center for Clinical Epidemiology and Biostatistics, and founding director of the graduate program in epidemiology and biostatistics, all at the Perelman School of Medicine of the University of Pennsylvania (Penn).

Dr. Strom earned a B.S. in molecular biophysics and biochemistry from Yale University in 1971, and then an M.D. from the Johns Hopkins University School of Medicine in 1975. From 1975 to 1978 he was an intern and resident in internal medicine and from 1978-1980 he was an NIH fellow in clinical pharmacology at the University of California, San Francisco. He simultaneously earned an M.P.H. degree in epidemiology at the University of California, Berkeley. He has been on the faculty of the University

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

of Pennsylvania School of Medicine since 1980. The Center for Clinical Epidemiology and Biostatistics (CCEB) that he created at Penn includes more than 550 faculty, research and support staff, and trainees. At the time Dr. Strom stepped down, CCEB research received nearly $49 million per year in extramural support. Its total budget was approximately $67 million.

Although Dr. Strom’s interests span many areas of clinical epidemiology, his major research interest is in the field of pharmacoepidemiology (i.e., the application of epidemiologic methods to the study of drug use and effects). He is recognized as a founder of this field and for his pioneer work in using large automated databases for research. He is editor of the field’s major text (now in its fifth edition) and editor-in-chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology. As one of many specific contributions, his research was pivotal in prompting the American Heart Association and American Dental Association to reverse 50 years of guidelines, and recommend against use of antibiotics to prevent infective endocarditis, instead of recommending for the widespread practice. In addition to writing more than 600 papers, and 11 books, he has been principal investigator for more than 275 grants, including more than $115 million in direct costs alone. Dr. Strom has been invited to give more than 400 talks outside his local area, including presentations as the keynote speaker for numerous international meetings. He has been a consultant to the National Institutes of Health (NIH), Food and Drug Administration (FDA), Centers for Disease Control and Prevention, US Pharmacopeial Convention (USP), Association of American Medical Colleges (AAMC), Joint Commission on Accreditation of Healthcare Organizations (JCAHO), foreign governments, most major pharmaceutical manufacturers, and many law firms.

Dr. Strom is also a nationally recognized leader in clinical research training. At the Perelman School of Medicine, Dr. Strom developed graduate training programs in epidemiology and biostatistics. More than 625 clinicians have been trained or are in training through the largest of these training programs, which leads to a Master of Science in clinical epidemiology degree. All but approximately 65 former trainees in this program have appointments in academic or other research institutions. Dr. Strom was principal investigator (PI) or Co-PI of 11 different NIH-funded training grants (T32, D43, K12, and K30), each of which supported clinical epidemiology trainees in different specialties and subspecialties, and has been the primary mentor for more than 40 former and current clinical research trainees and numerous junior faculty members. Internationally, Dr. Strom was a key contributor to the conceptualization and planning that led to the development of the International Clinical Epidemiology Network (INCLEN), created in 1979 with support provided by The Rockefeller Foundation to provide clinical research training to clinicians from selected

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

developing country sites. Penn was an INCLEN founding member and one of five training centers. INCLEN phase I, from 1979 through 1995, resulted in the establishment of 26 clinical epidemiology units in Africa, India, Latin America, India, and Southeast Asia. The Penn training program alone, led by Dr. Strom, trained 63 INCLEN trainees.

Dr. Strom was a member of the Board of Regents of the American College of Physicians, the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics, and the Board of Directors for the American College of Epidemiology, and is currently a member of the Board of Directors for the Association for Patient-Oriented Research. He was previously president of the International Society for Pharmacoepidemiology and the Association for Clinical Research Training. Dr. Strom was on the Drug Utilization Review Committee and the Gerontology Committee of the US Pharmacopoeia, served on the Drug Safety and Risk Management Advisory Committee for the FDA, chaired the Institute of Medicine (IOM) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, chaired the IOM Committee on Smallpox Vaccine Program Implementation, chaired the IOM Committee to Review NIOSH’s Traumatic Injury Program, chaired the IOM Committee on the Consequences of Reducing Sodium in the Population, was a member of the IOM Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and was a member of the IOM Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. He is currently a member of the National Academies of Sciences, Engineering, and Medicine’s Forum on Drug Discovery, Development, and Translation.

Dr. Strom is a member of the American Epidemiology Society, and is one of a handful of clinical epidemiologists ever elected to the American Society of Clinical Investigation and American Association of Physicians. He has also been an elected member of the National Academy of Medicine since 2001. Dr. Strom received the 2003 Rawls-Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology & Therapeutics, the Naomi M. Kanof Clinical Investigator Award of the Society for Investigative Dermatology, the George S. Pepper Professorship of Public Health and Preventive Medicine, and in 2006 he received the Sustained Scientific Excellence Award from the International Society for Pharmacoepidemiology. In addition, Dr. Strom was named the 2008 recipient of the John Phillips Memorial Award for Outstanding Work in Clinical Medicine. This award is from the American College of Physicians and is considered to be one of the highest awards in internal medicine. Dr. Strom also received the 2013 Association for Clinical and Translational Science/American Federation for Medical Research National Award for Career Achievement and Contribution to Clinical and Translational Science for translation from clinical use into public benefit and policy. Penn awards that Dr. Strom

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

received include the class of 1992 Class Teaching Award and the Samuel Martin Health Evaluation Sciences Research Award. Dr. Strom received the 2004 Christian R. and Mary F. Lindback Award, the university’s most prestigious teaching award, in recognition of the contribution he has made in his career to clinical research teaching.

Jon Kim Andrus, M.D., joined the Sabin Vaccine Institute in October 2014 where he serves as executive vice president and director of the Vaccine Advocacy and Education (VAE) program. VAE works to reduce the suffering caused by vaccine preventable diseases by bringing together key stakeholders to foster collaboration, share best practices, and develop improved vaccine policy and access. Previously, Dr. Andrus served as deputy director of the Pan American Health Organization (PAHO). Prior to that, he was the lead technical advisor for PAHO’s immunization program, providing oversight and guidance for technical cooperation to member countries.

Dr. Andrus holds faculty appointments at the University of California, San Francisco, and the Johns Hopkins Bloomberg School of Public Health. He began his global health career as a Peace Corps volunteer, serving as a district medical officer in Malawi and has since held positions in the Centers for Disease Control and Prevention’s (CDC’s) Global Immunization Division, as head of the, Vaccinology and Immunization Program at the Institute for Global Health at the Universities of California at San Francisco and Berkeley, and as director of the Global Health MPH Program at George Washington University.

Dr. Andrus has received numerous other awards for his leadership in the eradication of polio, measles, rubella, and congenital rubella syndrome, as well as the introduction of new vaccines in developing countries. In 2013, Dr. Andrus received the Transformational Leadership Award of the University of California. In 2011, he received the Global Leadership Award of the Pneumococcal Awareness Committee of Experts. In 2007, he received the Philip R. Horne Award for global leadership in immunization. In 2000, he received the Distinguished Service Medal, the highest award of the US Public Health Service, for his leadership in working to eradicate polio in Southeast Asia. Dr. Andrus holds a Bachelor of Science degree from Stanford University, obtained his medical degree from the University of California, Davis, and completed his residencies in family medicine at the University of California, San Francisco, School of Medicine, and preventive medicine at the CDC. He has published more than 100 scientific peer-reviewed papers on disease eradication, the introduction of new vaccines, and primary care.

Andrew Aronsohn, M.D., is an associate professor of medicine in the Center for Liver Diseases at the University of Chicago Medical Center.

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

Dr. Aronsohn is also a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago. Dr. Aronsohn is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat hepatitis C virus (HCV) in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting. Dr. Aronsohn is a member of the American Association for the Study of Liver Disease/Infectious Disease Society of America (AASLD/IDSA) HCV guidance writing committee and has a busy clinical practice which includes both general and transplant hepatology.

Daniel R. Church, M.P.H., is the viral hepatitis prevention coordinator and an epidemiologist in the Bureau of Infectious Disease at the Massachusetts Department of Public Health. In this role he has helped to develop and implement the statewide viral hepatitis program, including disease surveillance, medical management services, counseling and testing programs, adult vaccination programs, educational campaigns for providers, patients and communities, and evaluation of projects. He was a member of the Institute of Medicine committee that authored the report Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Mr. Church received his M.P.H. in epidemiology and biostatistics from the Boston University School of Public Health.

Seymour S. Cohen, Ph.D., has worked on bacterial viruses since 1945, offering the first systematic exploration of the biochemistry of virus-infected cells and of how viruses multiply. His subsequent research included delineating the phenomenon of thymineless death, developing derivatives of ara-A compound, working on RNA synthesis, studying the effects of poly-amines on metabolic systems, and studying plant viruses (including viral cations). Much of his research has contributed to the chemical treatment of cancer and viral infections.

Alison A. Evans, Sc.D., is an associate professor in the Department of Epidemiology and Biostatistics at the Drexel University Dornsife School of Public Health. She is also an adjunct research faculty member in the Public Health Program of the Hepatitis B Foundation, Doylestown, Pennsylvania. Prior to joining Drexel, she was an associate member at the Fox Chase Cancer Center. Her research interests include the epidemiology and natural history of the hepatitis B virus and other chronic viral infections, the association of chronic viral infections with cancer, and public health interventions to decrease the burden of HBV infection globally. She received her Sc.D. in epidemiology from the Harvard School of Public Health.

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

Paul Kuehnert, D.N.P., R.N., is a nurse and public health expert who currently oversees the Robert Wood Johnson Foundation’s work in building bridges among the health care system, public health, and other community services and agencies to improve overall population health. As a former county health officer in Illinois and former deputy state health officer in Maine, he brings extensive public health experience to the group. He has an acute awareness of the strengths of local and state public health agencies in combatting conditions such as hepatitis B and C as well as the challenges they face. He is extremely familiar with the topics of surveillance, implementation of disease control programs, screening, epidemiology, and community based program implementation (see in particular his prior work in HIV/AIDS).

Vincent Lo Re III, M.D., M.S.C.E., earned his medical degree from the University of Pennsylvania, completed an internship and residency in internal medicine and completed a fellowship in infectious diseases at the Hospital of the University of Pennsylvania (Penn). He also earned a Master of Science in clinical epidemiology degree from Penn. Dr. Lo Re has a nationally recognized clinical research program in viral hepatitis epidemiology. He joined the Penn faculty in 2008 and is currently an assistant professor of medicine in the Division of Infectious Diseases and assistant professor of epidemiology in the Department of Biostatistics and Epidemiology at Penn. He is also co-director of the HIV/Viral Hepatitis Scientific Working Group within the Penn Center for AIDS Research and a senior scholar in the Penn Center for Clinical Epidemiology and Biostatistics. Additionally, he is co-chair of the Liver Core of the Veterans Aging Cohort Study. He has been invited to speak on topics related to chronic viral hepatitis infection, HIV/viral hepatitis coinfection, and pharmacoepidemiology at ID Week, the Interscience Conference on Antimicrobial Agents and Chemotherapy, Conference on Retroviruses and Opportunistic Infections, the Food and Drug Administration (FDA), and the International Society for Pharmacoepidemiology. He has been a standing member of the FDA’s Antiviral Drug (now Anti-Infective) Advisory Committee since 2014. He also served as a member of the National Institute of Allergy and Infectious Diseases study section reviewing the Centers of Excellence for Influenza Research and Surveillance.

Kathleen Maurer, M.D., M.P.H., M.B.A., is the Connecticut Department of Correction’s director of health and addiction services and medical director. Before assuming her current post in 2011, she was assistant medical director at Correctional Managed Health Care, a division of the University of Connecticut Health Center, which contracts with the state corrections department for offender medical care. During her career, Dr. Maurer has

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

provided hands-on clinical care and medical program management in the private sector. In the realm of correctional care, she is particularly interested in the quality of patient care, in the role of correctional healthcare in the broader scope of public health such as in the treatment of hepatitis C virus in our offender-patients, and in facilitating reentry programs through integration of community and correctional healthcare. Several of her recent and ongoing initiatives include working to expand Medicaid access to halfway house residents and to integrate Medicaid utilization management with the correctional system. She is also developing a system-wide medication assisted therapy program for the Connecticut Department of Corrections. Dr. Maurer is the primary author of the monograph titled “Hepatitis C in Correctional Settings: Challenges and Opportunities,” published by the American Correctional Association. Dr. Maurer earned her M.D. from the Yale University School of Medicine. She also earned an M.P.H. from Yale. She holds an M.B.A. from the University of Connecticut and is board-certified in internal medicine, occupational and environmental medicine, and addiction medicine.

Randall R. Mayer, M.P.H., M.S., serves as interim director of the Division of Behavioral Health at the Iowa Department of Public Health. While working with the Iowa Department of Public Health, Mr. Mayer served as the chief of the Bureau of HIV, STD, and Hepatitis, HIV surveillance coordinator and the HIV and Hepatitis program manager. He received his M.P.H. in epidemiology from the University of Minnesota and his M.S. in plant cell physiology from Purdue University.

Shruti Mehta, Ph.D., M.P.H., is a professor in the Johns Hopkins Bloomberg School of Public Health. Her primary research interests include working with hard-to-reach populations to understand the epidemiology, natural and treated history of HIV, hepatitis C virus (HCV) and HIV/HCV coinfection; populations of interest include injection drug users and men who have sex with men as well as their sexual partners in both Baltimore and international settings, particularly India; special interest in identifying and overcoming barriers to care and treatment of HIV and hepatitis C virus among such populations.

Stuart C. Ray, M.D., serves as vice chair of medicine for Data Integrity and Analytics, associate fellowship program director and professor in the Division of Infectious Diseases within the Department of Medicine, with secondary appointments in Viral Oncology and Health Sciences Informatics, at the Johns Hopkins University School of Medicine. He directs the virology laboratory and is a clinical investigator in the Center for Viral Hepatitis Research in the Division of Infectious Diseases. He is a faculty member of

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

the graduate immunology program, the graduate pharmacology program, and of the Janeway Firm of the Osler Medical Service. Dr. Ray received his M.D. from the Vanderbilt University School of Medicine in 1990. After an internship and residency at Johns Hopkins Hospital, he continued there as an assistant chief of service and fellow in infectious diseases. During his fellowship, he studied the immunology and sequence variation of HIV in the laboratory of Dr. Robert Bollinger. During that time, he developed an interest in HIV sequence variation during antiretroviral therapy in a productive collaboration with Dr. Robert Siliciano that continues to the present.

In 1997, Dr. Ray joined the Johns Hopkins faculty, and under the mentorship of Dr. David Thomas shifted his primary research focus to hepatitis C virus (HCV). His laboratory work has focused on the sequence variation of HCV during acute and chronic infection, developing and applying computational and molecular biology tools to underlying mechanisms, including stochastic variation, immune selection, and viral fitness. He continues to care for inpatients and outpatients with HIV, HCV, and other infectious diseases.

Arthur L. Reingold, M.D., is Edward Penhoet Distinguished Professor of Global Health and Infectious Diseases at the School of Public Health, University of California, Berkeley (UCB). He is also professor of epidemiology and biostatistics and clinical professor of medicine at the University of California, San Francisco (UCSF). His research interests include emerging and reemerging infections and vaccine-preventable diseases in the United States and developing countries. Dr. Reingold serves on the World Health Organization’s Strategic Advisory Group of Experts on vaccines and vaccine policy as vice-chair. He is also director of the California Emerging Infections Program, and of the National Institutes of Health Fogarty AIDS International Training and Research Program at UCB/UCSF. His recent publications include articles on the impact of the introduction of pneumococcal conjugate vaccine in the United States and related topics. Before joining the faculty at UCB, Dr. Reingold worked for 8 years at the Centers for Disease Control and Prevention. He is a member of the National Academy of Medicine.

Samuel So, M.B.B.S., is a professor of surgery and the Lui Hac Minh Professor at Stanford University. He is also the director of the Asian Liver Center and director of the Multidisciplinary Liver Cancer Program at the same institution. He has published numerous studies on solid organ transplantation, gastric and liver cancers. Dr. So is well known for his work on hepatitis B and liver cancer education and prevention programs. Through his research, Dr. So has identified the need for a public health approach to liver cancer prevention among recent Asian immigrants and first and second generation Asians living in the United States. These populations have

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

not been the typical focus of US screening and prevention programs. Dr. So is listed among the Best Doctors in America published by Woodward/White Inc. For his work in education and prevention, he received the 2005 National Leadership Award from the New York University Center for the Study of Asian American Health, and the 2008 American Liver Foundation Salute to Excellence Award. He is a member of the National Academies of Sciences, Engineering, and Medicine’s Board on Population Health and Public Health Practice. Dr. So received his M.B. and B.S. in medicine and surgery from the University of Hong Kong and did postdoctoral and clinical fellowships at the University of Minnesota.

Neeraj Sood, Ph.D., is the vice dean for research at the University of Southern California (USC) Price School of Public Policy. In addition, he currently serves as the director of research at the Leonard D. Schaeffer Center for Health Policy and Economics and is an associate professor at the Price School and the School of Pharmacy’s Department of Pharmaceutical and Health Economics. His prior work has focused on the economics of innovation, HIV/AIDS, health care financing, and global health.

His research has been published in several peer-reviewed journals and books including leading journals in economics, medicine and health policy. He has testified frequently on health policy issues before state legislators and his work has also been featured in several media outlets including The New York Times, The Washington Post, U.S. News & World Report, and Scientific American. Dr. Sood was the finalist for the 16th and 21st Annual National Institute for Health Care Management Foundation (NIHCM) Health Care Research Award, recognizing outstanding research in health policy. He was also the 2009 recipient of the Eugene Garfield Economic Impact Prize, recognizing outstanding research demonstrating how medical research impacts the economy.

Dr. Sood is on the editorial boards of Health Services Research and Forum for Health Economics and Policy and is a research associate at the National Bureau of Economic Research. Prior to joining USC, Dr. Sood was a senior economist at RAND and professor at the Pardee RAND Graduate School.

Grace Wang, M.D., M.P.H., is a board certified family physician for International Community Health Services in Seattle, Washington. Dr. Wang graduated from the University of Michigan with a degree in early childhood education. She received her medical training at Cornell University Medical College in New York City and has a master’s in public health also from the University of Michigan. Dr. Wang has worked in primary care and public health in New York City and Seattle. She is currently a member of the Executive Committee for the National Association of Community Health

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×

Centers board of directors and also serves on the boards for Project Access Northwest and Kin On.

Lucy E. Wilson, M.D., Sc.M., is a medical epidemiologist and infectious disease physician at the Maryland Department of Health and Mental Hygiene, where she serves as the chief of the Center for Surveillance, Infection Prevention and Outbreak Response. At the state of Maryland, Dr. Wilson implements surveillance and prevention of reportable infectious diseases (including hepatitis B and C infections), consults on infection control issues across the healthcare continuum and in the general community, and oversees Maryland’s outbreak responses, including food-related outbreaks, novel influenza pandemic response, and Ebola virus disease response. Dr. Wilson is the principal investigator of the Healthcare Associated Infections (HAI) branch of the Centers for Disease Control and Prevention (CDC)/Maryland Emerging Infections Program, conducting HAI surveillance and prevention research and is the medical advisor for the CDC grant “Community-based Programs to Test and Cure Hepatitis C” in Maryland. Dr. Wilson is an adjunct assistant professor at the Johns Hopkins University School of Medicine, where she previously was on the Johns Hopkins School of Medicine Division of Infectious Diseases faculty as the medical director of the Johns Hopkins HIV County Program, and where her research focused on the natural history of hepatitis C in injection drug users and HIV clinical outcomes research.

Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 147
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 148
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 149
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 150
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 151
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 152
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 153
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 154
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 155
Suggested Citation:"Appendix C: Committee Biographies." National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press. doi: 10.17226/23407.
×
Page 156
Next: Appendix D: Glossary »
Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report Get This Book
×
Buy Paperback | $64.00 Buy Ebook | $49.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world’s hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide.

The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!